UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 66 filers reported holding UROGEN PHARMA LTD in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $187,000 | -6.0% | 22,801 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $199,000 | -50.7% | 22,801 | -46.4% | 0.00% | -33.3% |
| Q4 2021 | $404,000 | -43.8% | 42,501 | 0.0% | 0.00% | -40.0% |
| Q3 2021 | $719,000 | +10.8% | 42,501 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $649,000 | -21.6% | 42,501 | 0.0% | 0.01% | -37.5% |
| Q1 2021 | $828,000 | +95.7% | 42,501 | +80.8% | 0.01% | 0.0% |
| Q4 2020 | $423,000 | -6.6% | 23,501 | 0.0% | 0.01% | -27.3% |
| Q3 2020 | $453,000 | -26.2% | 23,501 | 0.0% | 0.01% | -38.9% |
| Q2 2020 | $614,000 | +46.5% | 23,501 | 0.0% | 0.02% | -10.0% |
| Q1 2020 | $419,000 | -52.0% | 23,501 | -10.2% | 0.02% | -20.0% |
| Q4 2019 | $873,000 | +40.8% | 26,172 | 0.0% | 0.02% | +4.2% |
| Q3 2019 | $620,000 | -33.4% | 26,172 | +1.1% | 0.02% | -38.5% |
| Q2 2019 | $931,000 | +2.1% | 25,892 | +4.8% | 0.04% | -7.1% |
| Q1 2019 | $912,000 | -14.2% | 24,698 | 0.0% | 0.04% | -10.6% |
| Q4 2018 | $1,063,000 | – | 24,698 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |